ADMA Biologics Inc (ADMA)

Solvency ratios

	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Debt-to-assets ratio	0.26	0.35	0.37	0.40	0.41	0.41	0.42	0.41	0.47	0.47	0.45	0.34	0.40	0.40	0.40	0.45	0.51	0.50	0.46	0.54
Debt-to-capital ratio	0.30	0.41	0.46	0.49	0.48	0.49	0.50	0.48	0.58	0.55	0.52	0.40	0.48	0.46	0.45	0.51	0.58	0.56	0.50	0.72
Debt-to-equity ratio	0.44	0.70	0.85	0.97	0.94	0.96	0.99	0.94	1.41	1.22	1.09	0.67	0.92	0.84	0.83	1.05	1.36	1.26	1.00	2.61
Financial leverage ratio	1.68	2.00	2.28	2.43	2.30	2.34	2.34	2.29	2.99	2.60	2.43	1.96	2.32	2.09	2.09	2.35	2.66	2.49	2.19	4.85

ADMA Biologics Inc's solvency ratios have shown fluctuations over the periods analyzed. The debt-to-assets ratio decreased from 0.54 in December 2019 to 0.26 in September 2024, indicating an improvement in the company's ability to cover its assets with debt.

Similarly, the debt-to-capital ratio decreased from 0.72 in December 2019 to 0.30 in September 2024, showing a reduction in the proportion of debt used to finance the company's capital structure.

In contrast, the debt-to-equity ratio fluctuated more significantly, ranging from 0.67 in March 2022 to 2.61 in June 2021. This indicates varying levels of leverage and financial risk for the company over the periods examined.

The financial leverage ratio also showed fluctuations, ranging from 1.96 in December 2021 to 4.85 in June 2020. This ratio reflects the company's overall financial risk and leverage relative to its equity.

Overall, the trend in the solvency ratios suggests that ADMA Biologics Inc has made efforts to reduce its reliance on debt and improve its financial stability over the periods analyzed. Continued monitoring of these ratios will be important to assess the company's long-term financial health and risk management strategies.

Coverage ratios

	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019
Interest coverage	16.59	6.44	1.97	0.86	0.05	-0.70	-1.15	-2.04	-2.76	-3.54	-4.38	-4.47	-4.86	-4.89	-5.08	-5.42	-4.78	-4.55	-4.42	-4.61

The interest coverage ratio for ADMA Biologics Inc has fluctuated significantly over the periods provided. Starting from negative values in December 2019 through June 2023, the company's interest coverage indicates a consistent inability to cover its interest expenses with its operating income. However, there is a marked improvement in the most recent periods, with the ratio steadily increasing to 16.59 in September 2024.

This positive trend suggests that ADMA Biologics Inc has managed to enhance its ability to meet interest payments from its operating earnings, indicating a better financial health and reduced risk of default. Investors and creditors may find the improving interest coverage ratio favorable, as it indicates a lower risk of insolvency and a strengthening financial position for the company.